I hope you all are enjoying your summer following our stimulating meeting in Montreal. The great majority of feedback indicated that downtown Montreal was a well-received site for our conference. My first note to the membership in my new role as President of CPDD is to express great thanks and appreciation to Leonard Howell for his outstanding leadership during the past year. Leonard guided our organization toward a more stable financial grounding, stimulated a more vibrant presence of preclinical science at our meeting, and initiated numerous innovative projects to help CPDD continue to evolve to best serve our members and the public health. I hope to continue the momentum he has generated in all these areas by not only continuing ongoing efforts, but by seeking more input and action from our membership to develop an even stronger scientific organization that is built for the future.

As most of you are aware, CPDD is a “membership” organization, which means your elected Officers and the Board of Directors work to support and serve the members’ interests. Just to remind you of CPDD’s mission, here is the official mission statement located on our website,

“The College on Problems of Drug Dependence (CPDD) provides a national and international forum for scientists of diverse backgrounds to advance the understanding of molecular-neurobiological, behavioral, and epidemiological* aspects of addictive disorders and, by the application of new scientific knowledge, to improve and develop treatments utilizing novel behavioral and pharmacological therapies. Through associations with academia, government agencies and private industry, CPDD is able to promote scientific discoveries in addictive diseases as well as to inform legislators about their implications for public policy, benefits to society and the need for continued advancement of science and education on addictive diseases. The College also nurtures training and development of basic and clinical scientists in these fields.”

*italicized text added invoking editorial privilege

Before I look to encourage and motivate your participation in our organization, I would like to acknowledge and express appreciation for the service of a number of individuals, and provide a few quick updates.

First, we all owe much gratitude to Bill Dewey, who, after serving CPDD as its Public Policy Officer for many years, will be stepping aside. Bill has put countless hours into working with our liaisons to the U.S. Congress and the White House to educate and advocate for the best interests of addiction scientists and the public who benefit from the research we do. We are fortunate that our Past-President, Sandy Comer, will be
assuming the responsibilities of Public Policy Officer. Sandy has been working closely with Bill and colleagues over the past 3 years and is more than ready to keep the pedal to the metal in advancing the cause. In that regard, Sandy organized CPDD’s first-ever "Advocacy Day" last March, when a number of us visited our representatives in Washington, DC to provide education about the importance of research in solving the ongoing public health issues related to substance use and addiction. In case you are wondering, Bill isn't going anywhere. Bill will continue his work with Friends of NIDA, and Sandy and the Board still plan to make great use of his wealth of knowledge and sage advice.

Next, I would like to recognize and again express great appreciation to Linda Cottler, who served as our Treasurer over the past three years. CPDD's transition, post the Marty Adler era, brought many challenges, not the least of which were in the financial arena. Linda put in many hours working with the Executive Office and Committee and the Board of Directors to ensure that we were on solid ground with our financial operations and our assets. We now have a clear vision of where we stand, and how to proceed. Jack Bergman has stepped up to assume the Treasurer role. With Jack's experience, we are sure to continue on a positive course in the financial arena.

I am also very pleased to recognize Meg Haney for being elected President-Elect. Meg has now joined the Executive Committee and will provide invaluable input and guidance to CPDD for the next three years. I very much look forward to working with Meg in the coming years. Please congratulate Meg if you get the chance.

Last, I would like to acknowledge Loretta Finnegan in her role as CEO. Loretta finished her first term, and was voted by the Board to receive another 3-year contract to continue in this role. Following Marty Adler into the CEO position was like following Bear Bryant, Pat Summitt, Eddie Robinson, Casey Stengel, Red Auerbach, or John Wooden, pick your sports coaching legend analogy. You are destined to unfair and unrelenting comparisons, and few are ever satisfied. Loretta has weathered that initial period with remarkably few wounds. She has provided CPDD with a stable voice and has helped us on our path to continued and future success!

Now back to you. Your input on, and service to, CPDD is highly valued. We (the Executive Committee and Board of Directors) are continually evaluating and brainstorming about (a) all aspects of our annual conference -- scientific program, location, length of conference, poster logistics, food services, registration fees and logistics, etc., (b) new ways to attract new members and engage current members, (c) better ways to facilitate communication among the membership, and (d) how to stabilize finances without increasing costs to members or reducing value, among many other things.

A major focus of my year as President will be to explore ways to make more members feel the way I do about CPDD; that is, cherish it as my scientific home. CPDD is probably the largest and most scientifically diverse professional/academic organization focused specifically on addiction. Our challenge is to identify what about CPDD facilitates strong ties or bonding to the organization and the annual conference. What makes those in our field want to come back year after year? For me, I think it may be its scientific diversity, which is captured in a meeting large enough to offer strong programming in various areas, but small enough that scientists within and across areas can network and socialize. Moreover, I think it is CPDD's strong commitment and contributions to shaping our national research agenda, regulatory policies, and public policy related to substance use, misuse and addiction. Feeling like one understands the bigger picture and can make an impact in multiple ways can provide valuable meaning to scientists' professional lives. The breadth and extended focus of CPDD can lead individual colleges and

Continued on page 3
Continued on page 4
Fellowship for his work with the NVHL rat, and received an excellent score on a K99, which he hopes may be funded soon.

Jibran has been busy disseminating findings from this research via presentations at the CPDD, the Research Society on Alcoholism (with another travel award), the American Psychiatric Association, and the International Congress on Dual Disorders, among others. He has multiple first author and co-author publications from this research in a diversity of scientific journals (e.g., *Neuropsychopharmacology, Drug and Alcohol Dependence, Schizophrenia Research*) and has numerous others under review or in preparation. In addition, Jibran has already begun to provide service with multiple scientific organizations, at Dartmouth College (IACUC member), and has been mentoring and teaching undergraduates and graduate students. In summary, Jibran Khokhar is an exemplar recipient of the Holtzman Award. His preclinical research truly embraces a translational and applied approach to science, and has already begun to impact the field. Congratulations are deserved! We look forward to many years of contributions and collaborations that serve the field of drug dependence and mental health.

**Jibran Y. Khokhar, Ph.D.**

It is an absolute honor to receive the 3rd Annual Stephen G. Holtzman Travel Award for Preclinical Investigators. As a young behavioral pharmacologist, receiving an award named after Dr. Holtzman is something I cherish deeply. After all, as scientists, we stand on the shoulders of giants like Dr. Holtzman. I have also been fortunate to have had giants like Drs. Rachel Tyndale, Alan Green, Alan Budney and Elliot Stein as mentors and would not have been deserving of this award without their continued support and advice. I would like to thank the CPDD as well as Dr. Holtzman and his family for their generous support, as well my mentors, and look forward to continuing to serve as a member of the college.

**Marian Fischman Lectureship Award:**

*Sharon Walsh, Ph.D.*

*(Introductory remarks by Michelle Loftwall)*

It is my pleasure to introduce Dr. Sharon Walsh, this year’s awardee of the Marian Fischman Award. This award aims “to recognize the contribution of an outstanding woman scientist in drug abuse research”, and Sharon certainly is highly deserving of this recognition. Sharon and Marian had careers that mirrored each other in many ways. I’ve learned from several of Sharon’s nominators, Drs. Balster, Bigelow and Finnegan, that both began their careers in animal research, moved into human lab doing behavioral pharmacology research during their post-doctoral fellowship, and had very successful careers in the area of behavioral pharmacology medication development that led to clinical trial research. Both spent productive years on the faculty at Johns Hopkins - overlapping for two of those years. In addition, both have records as superior mentors that I can personally attest to as well, significant accomplishments in translating science into policy and regulation, and important leadership responsibilities in the CPDD. For instance, Sharon has served as the Chair of the Scientific Program Committee, Board Member and is a Past President. Sharon and Marian both accomplished all of this while raising a family and being role models for aspiring women scientists. Sharon has too many important research accomplishments to review thoroughly. Just as examples, Sharon’s laboratory
studies with buprenorphine led to its assessment in clinical trials, and ultimately FDA approval for opioid dependence treatment. She has also done critical work elucidating the abuse liability of prescription opioids commonly prescribed that contributed to the up-scheduling of hydrocodone. Dr. Walsh’s work has led to her being selected for some very prestigious awards. For example, she received the Presidential Early Career Award for Scientists and Engineers. This award is the highest honor bestowed by the U.S. Government on outstanding scientists and engineers beginning their independent careers. In 2000, she received the College on Problems of Drug Dependence (CPDD) Joseph Cochin Award, recognizing her as the best among all drug abuse scientists in the country for her early career contributions. Overall, it is very clear that Marian was beloved and I think the same can be said of Sharon. It is my honor to now have Dr. Sharon Walsh come up here to the podium, accept this award, and deliver the Marian W. Fischman Lectureship.

**Sharon Walsh, Ph.D. (excerpts from her remarks)**

I really want to thank the people who nominated me for this award. I want to thank Michelle Lofwall who led the charge. She is, and has been, a colleague of mine for a very long time, a very dear friend and someone I learn from every day. George Bigelow, who wrote a letter as well, and who is the best mentor that anyone could ever ask for, and I’m the luckiest girl in the world. Also, Bob Balster, who is a very dear friend and a long-standing colleague, and I would be remiss if I didn’t thank Loretta Finnegan, because she tried to get me nominated for this award years ago before she took over being in charge of CPDD and became hopelessly in conflict. She was very, very supportive of that. I also want to thank the Awards Committee. I know that they get many nominations for all the awards and I’m certain that the deliberations are very challenging every year. Finally, I want to thank the College itself, which has provided me with a scientific home for the last 25 years under the leadership of Marty Adler and now under Loretta’s leadership. There are too many individual people for me to thank along the way, because I would leave somebody out and I’ve covered a broad range of work—post-doctoral fellows, students, research assistants, nurses, colleagues, NIDA project officers, and NIDA itself for funding. I also want to give a special thanks to Paul Nuzzo. I’ve known Paul for 20 years. I hired Paul as a research assistant and it was his first job out of college and we’ve been together ever since. Amazingly, because the first study that he was ever assigned to was to administer a full kappa agonist to humans and it wasn’t a pretty site, but he stuck with me and he serves as our statistician. We worked together at Hopkins and now at UK, manager, trainer, and he is just an extraordinary collaborator. And with that I want to thank the very best club of all, which is my family and my husband Patrick, and in the upper picture you can see that the children once were little and it’s hard to believe that they are all so big, and with that thank you for your attention.

**CPDD Mentorship Award: Stephen Higgins, Ph.D.**

*(Introductory remarks by Alan Budney)*

This year's recipient of the CPDD Mentoring Award, Dr. Stephen T. Higgins, fulfills all intentions and expectations of this highly coveted honor. Steve is Director of the Vermont Center on Behavior and Health, Professor and Virginia H. Donaldson Chair in Translational Science in the Departments of Psychiatry and Psychology and Vice Chair of Research in the Department of Psychiatry at the University of Vermont. His track record in addictions research is exemplary with over 300 publications in journals, book chapters, and books, and an enviable history of research funding. He is currently
supported by P20 and P50 center grants, two R01s, and a T32 from the National Institute on General Medical Sciences, the Food and Drug Administration, the National Institute on Drug Abuse, and the National Institute of Child Health and Human Development. Accomplished and successful researchers not only conduct cutting-edge science, but they communicate it clearly, and represent and lead their scientific peers to afford maximal impact on their field and ensure its continuity and growth. Steve clearly embodies these scientific qualities and values, and this may be best illustrated by the records of his trainees. Over the past 28 years, Steve has mentored 22 pre- and post-doctoral trainees, as well as countless undergraduates, research assistants, and junior faculty. The vast majority of his trainees have remained active in academic research and have developed their own productive careers in his footsteps.

**Stephen Higgins, Ph.D.**

This is a wonderful honor for which I am deeply thankful. I want to thank Drs. Alan Budney and Craig Rush for taking time out from their busy schedules to nominate me, and to Alan for his thoughtful and generous Introduction. I began my mentoring career approximately 30 years ago with Alan and Craig as my postdoc and graduate student, respectively. Starting things off with those two was certainly a sign of good fortune for me, and a real blast. We worked hard, Craig in the clinical laboratory and Alan overseeing projects in the clinic, but being close in age we also did a good bit of socializing, skiing, etc., together. We had fun—probably a tad too much at times. What is really terrific about kicking off a mentoring career early in one’s career is you have the opportunity for long careers together as colleagues. I have thoroughly enjoyed my relationships with Alan and Craig throughout.

I want to thank the CPDD Awards committee for selecting me for this award from among my many very deserving CPDD colleagues. I also want to thank the College for supporting a Mentorship award. Obviously mentoring is key to the future of our field and it is great that the College devotes resources to forwarding that mission. To stand among the distinguished list of former awardees is a distinct honor. Given my particular specialty, and training history going back to a postdoctoral fellowship at Johns Hopkins, three former awardees particularly stand out—Joe Brady who started in one way or another virtually everything at Johns Hopkins having to do with drug abuse and behavioral pharmacology, Bob Schuster who was Joe’s student and, of course, went on to so many wonderful professional accomplishments, and George Bigelow, another of Joe’s former students, who similarly went on to wonderful accomplishments. Wow, what an honor to stand among such accomplished colleagues and friends.

I want to thank NIDA for continuously supporting the University of Vermont’s T32 training program over the past 28 years. That award made this day possible. Thanks to the NIDA project officers, Dr. Cece McNamara Spitznas for many of the early years and Dr. Will Aklin more recently, who have been terrific to work with—always supportive, generous, and positive. The T32 is a terrific mechanism. I say that standing here looking out at my postdoctoral mentors, Drs. Maxine Stitzer George Bigelow sitting there in the audience, whose NIDA T32 made my career in addictions research possible. I can’t speak for Maxine or George but strongly suspect that they would share my enthusiastic assessment of the many merits of this terrific mechanism and the excellent job that NIDA does administering it. To show just how thoroughly intertwined the T32 mechanism is to so many of our careers, I had the distinct pleasure in the past couple of weeks of participating in the annual NIDA T32 retreat for the impressive new training program in addictions research that Alan Budney and
Award Winners continued from page 6
colleagues established at Dartmouth College. What a treat that was!

In many ways, I feel that I am receiving this award on behalf of my colleagues who have worked shoulder to shoulder with me over the many years devoted to making the University of Vermont’s training program a success. It began with my dear colleague and friend Dr. Warren Bickel. Warren took the lead in our effort to obtain a T32, with Dr. John Hughes and I as Assistant Professors assisting him with getting the training program off the ground. We had a terrific run together for almost 20 years and of course John is still involved today. Alan Budney stayed on as faculty after completing his training and the four of us worked together for a good number of years. Then when Alan and Warren headed off to the University of Arkansas, where they again started a T32 training program, Drs. Sarah Heil and Stacey Sigmon stepped into the role of mentors, roles in which they have been outstanding. They deserve a tremendous amount of credit. Sarah and Stacey had been postdoc and graduate student with me, respectively, and again I had the pleasure of finding myself mentoring shoulder to shoulder with former students, which is another terrific experience about which I’ll say more in a minute. More recently, Drs. Diann Gaalema, Andrea Villanti, and Allison Kurti have joined our mentoring team and I look forward to working with them. Thanks to each of you!

And now a direct and heartfelt thank you to each of the students with whom I have had the honor to work, both as primary mentor and as a secondary mentor with the many others who came through the UVM training program working primarily with one of the colleagues mentioned above. You have been terrific! Of course, mentoring is not always easy and so as a behavioral pharmacologist by training I have found myself at times pondering the question that those of us trained in that tradition are apt to ask—what maintains this behavior, what is the reinforcer for mentoring? Of course, I’m not sure, but what I suspect is for me those moments when you see students find their stride—when they do something professionally as an investigator or mentor that is clearly very good and you see it. Wow, what a distinct, emotionally positive experience. It’s hard to discern such moments in one’s own career where things sort of run together over the years. But with students I find that I can recall things much more clearly. I can see them in my mind’s eye sitting across from me early in their career just trying to get oriented to things in professional life. The contrast is quite salient. For me, it is those moments of former students in stride that are the reinforcers, the heroin equivalent, in a mentoring career.

My heartfelt thanks to all for this wonderful honor!

Nathan B. Eddy Memorial Award: Walter Ling, M.D.

(Introductory remarks by Peggy Compton)

Dr. Ling’s outstanding contributions to the science of substance use disorders and treatment over the past 45 years have significantly advanced our knowledge of the disease and undoubtedly helped thousands of individuals engage in recovery. His highly regarded and influential work has shaped current thinking about addiction and continues to add to our understanding of this complex and life-threatening disorder.

Dr. Ling’s in-depth understanding of substance use disorders is founded in his extensive background as a clinician. Having trained and practiced as a psychiatrist and neurologist, Dr. Ling brought a distinct neuropsychiatric perspective to his work and the work of others, and he continues to be recognized as one of the world’s leading clinical researchers in the field of addiction. His research activities have focused on the development and evaluation of pharmacotherapies and behavioral interventions for all

Continued on page 8
substance use disorders, with a special focus on opioid addiction. In addition, he has been a leader in the transfer of research-proven treatment protocols into practice in real-world healthcare systems across the nation and around the world. Dr. Ling’s international leadership has substantially advanced addiction medicine, and he has served as an effective and valued ambassador and an agent of change in promoting the role of addiction science and evidence-based treatment in many parts of the world. His efforts in developing the drug treatment systems now emerging in China, Thailand, Vietnam, Iraq, South Africa, Taiwan, and Egypt warrant particular consideration for their impact on large populations with extensive drug problems, including related consequences such as HIV infection.

Throughout his career, Dr. Ling has been one of the major contributors to the development of pharmacotherapies for opioid addiction. Responding to urgent calls for additions to the armamentarium targeting opioid addiction, he led several of the seminal studies that enabled FDA approval of LAAM, seen as an alternative to methadone. He also conducted one of the largest of the clinical trials that provided pivotal data leading to the approval of buprenorphine. Dr. Ling was the Lead or Co-Lead Investigator for buprenorphine studies conducted across the nation in community-based settings. The data amassed and the practical lessons learned during these trials contributed to the approval of buprenorphine as a treatment for opioid addiction, which has proven to be a useful medication that greatly advanced pharmacotherapy-based treatment for opioid addiction by allowing office-based management of patients by mainstream physicians. The enabling of office-based buprenorphine treatment has fundamentally changed the clinical practice addressing opioid addiction, reaching new populations of opioid users, and Dr. Ling has played an important leadership role in the development and implementation of buprenorphine treatment in primary care settings. He led an investigation of depot buprenorphine, delivered via a subcutaneous implant and providing stable medication effect for six months; this research was reported in an article co-authored by Dr. Ling and published in JAMA. As demonstrated by his work on sublingual buprenorphine, this exciting new treatment option could revolutionize the management of opioid addiction. Approval of this agent by the FDA was largely supported by data acquired by Dr. Ling’s research. This work becomes especially relevant and important when considered in the current context of what the CDC and others call an opioid epidemic, resulting in overdose deaths increasing rapidly over the past decade.

Similar to his efforts with depot buprenorphine, Dr. Ling also was involved in research to examine the clinical utility of depot naltrexone for the treatment of opioid addiction. Results of a seminal, large-scale Phase III trial were published with Dr. Ling as a co-author. On the basis of the trial results, Vivitrol® was approved by the FDA for treatment of opioid addiction. Dr. Ling also developed research to examine the utility of depot naltrexone in other drug use disorders, including methamphetamine dependence, for which no medication is approved. Dr. Ling has an uncanny ability to understand the data needed by the FDA to review and approve a new medication, and he designs and conducts studies that reflect cutting-edge scientific thinking in furtherance of decision-making by regulatory agencies. Furthermore, he has conducted research on psychosocial strategies to optimize outcomes of pharmacotherapy-based treatment.

Dr. Ling has been a faculty member in the UCLA Department of Psychiatry since 1971, but most of his research has occurred in community-based settings outside academia. During the 1970s, he was a leader within the Veterans Affairs system and contributed greatly to the creation of its addiction research capability, guiding junior researchers to productive careers that extend beyond the VA. In the 1980s,
working with Friends Research Institute and the Matrix Institute on Addictions, he established a network of clinical research sites in the Los Angeles area, providing a stable platform for clinical research and training of new clinicians and scientists. In the late 1990s, Dr. Ling was a major force behind the creation of the Integrated Substance Abuse Programs (ISAP), institutionally sited in the UCLA Department of Psychiatry and Biobehavioral Sciences. His goal was to assemble a team of scientists, clinicians, and support personnel into an organization that reflected his interdisciplinary approach to the study of addiction, associated problems, and innovative treatments. Directed by Dr. Ling since its inception, UCLA ISAP united the resources of several prominent research and clinical groups that conducted addiction research and treatment development. What emerged was a cohesive entity that has become a very productive academic-based research and training organization with national and international impact.

**Walter Ling, M.D.**

What does the Nathan B. Eddy award really mean for the recipient? How does one respond to a gift of such high honor? It was for me the occasion to reflect on all the unlikely events along the way, whether they were accidents or miracles, that led to this moment. The award gave me the opportunity to say thank you to all the friends and colleagues that helped shape those events, and to share a few memorable moments. A colleague commented in jest that it was perhaps the only acceptance comments that did not show any impact. Or miracles, that led to this moment. The award gave me the opportunity to say thank you to all the friends and colleagues that helped shape those events, and to share a few memorable moments. A colleague commented in jest that it was perhaps the only acceptance comments that did not show any data, and he had a very good point. For me, the award was not meant to induce a recap of my work; it was a wonderful occasion for me to say, “Thank you for being part of my life; I appreciate that you were there and will cherish you as I will cherish this award.”

**Joseph Cochin Young Investigator Award:**

**Matthew Banks, Ph.D.**

*(Introductory remarks by S. Steven Negus)*

The 2017 Joseph Cochin Award winner Matthew (Matt) Banks has made significant contributions to preclinical drug abuse research. A major focus of Matt’s recent work has been on use of drug-vs.-food choice procedures in rhesus monkeys to examine candidate medications for treatment of drug abuse. This work has culminated in publication of several impactful review articles on topics that include the determinants of drug vs. food choice in general, the use of choice procedures in medications development for cocaine and methamphetamine abuse, and the use of nonhuman primates in drug abuse research. In addition, Matt is now collaborating with colleagues at the Scripps Research Institute to develop vaccines for treatment of opioid addiction, and the first paper on their work was just published. Overall, Matt has published more than 70 research papers and reviews.

When you receive an email from Matt, his signature block always includes inspirational quotes. For example, one quote by Winston Churchill reads “Success is the ability to go from one failure to another with no loss of enthusiasm.” Like any good scientist, Matt has encountered his fair share of
failures, but he makes a habit of learning from them and advancing on to an even greater share of successes. We celebrate both his persistence and his successes today by awarding Matt the 2017 Joseph Cochin Young Investigator Award.

Matthew Banks, Ph.D.

I am deeply humbled and honored to stand up here as the 2017 Joseph Cochin Young Investigator Award winner. Alison Wakeford mentioned in her ISGIDAR talk yesterday that it takes a village to raise a scientist. I wholeheartedly agree with that statement and would not be standing up here accepting this award without the support of my village. Although there are a significant number of individuals in this audience who have contributed to my scientific career, I would like to take a brief moment to acknowledge some members of my “village.” Dr. Jon Sprague at Ohio Northern University provided me the initial opportunity to conduct basic pharmacology research as a pharmacy student. Dr. Michael Nader at Wake Forest University was my graduate advisor and he continues to influence my scientific career to this day. Drs. Leonard Howell and Steve Negus were my postdoctoral mentors and also shaped my research and mentoring behavior. One of the most significant traits of these mentors is that they still regularly interact with each of them. Dr. Bill Dewey is my Department Chair and has given me all the support that I have needed. In conclusion, I would ask you to emit two behaviors. First, thank your mentor. Second, when the opportunity arises for you to mentor and support the development of the next generation of scientists, pay it forward.

CPDD/NIDA Media Award: Sam Quinones
(Introductory remarks by Meg Chisolm)

It is my privilege to present this year’s CPDD/NIDA Media Award to journalist Sam Quinones in honor of his highly acclaimed book Dreamland: The True Tale of America’s Opiate Epidemic. In Dreamland, Quinones skillfully interweaves several major threads, all of which converge to create the horrific tapestry we now call the opioid epidemic. Like other great works of nonfiction, such as Jon Krakauer’s Into Thin Air, Michael Lewis’ Moneyball, and Erik Larson’s The Devil in the White City, Dreamland reads more like the best John Grisham novel than the super sad true story it is. Quinones somehow manages to grippingly describe how physicians are trained to understand, assess and manage chronic pain – including the introduction of the American Pain Society’s trademarked slogan “Pain: the fifth vital sign.” Quinones tells of the increased production and aggressive marketing of opioid pain relievers to physicians, and the story of the philanthropist Arthur Sackler – a psychiatrist turned Perdue executive. Quinones details the impact of this increased production and marketing – especially of Oxycontin - on prescribing practices, including the opening of “pill mills” and “pain centers.” Quinones takes us to cities and towns across middle America where Mexican farm boys are paid a salary to deliver black tar heroin - like pizza - directly to opioid users in Walmart parking lots and local fast food joints. Quinones paints a vivid picture of US rust belt towns devastated by high unemployment and the associated fraying of community ties. Into these narrative threads, Quinones integrates scientific research findings on the pharmacological action of opioids and evidence-based medication and behavioral treatments. He chronicles the history of our organization from its beginnings as the Committee on Problems of Drug Dependence, as well as the history of the US Narcotic Farm and its Addiction Research Center. Along the way, he interviews

Continued on page 11
several prominent CPDD members, including emeritus Executive Officer Marty Adler.

But - most importantly - throughout Dreamland Quinones gives voice to the stories of family members and their loved ones whose lives have been intimately affected - often tragically - by opioid use. Stories like those of the Schoonover’s - from Columbus Ohio - whose 19-year old son Matt died of a black tar heroin overdose, just one day after being discharged from rehab. Matt was on his way to an NA meeting and took a fatal detour.


And this year I’m honored to say that Dreamland is our favorite book. Please join me in recognizing Sam Quinones as the recipient of the 2017 CPDD/NIDA Media Award.

Sam Quinones (excerpts from his remarks)

In 2013, I was trying to understand all of this as a layman. I’m a crime reporter. I love talking to drug traffickers, immigrants and gang members. I do not talk with scientists too much. I went to your 2013 meeting. I went to get educated. That’s what you do as a reporter and you don’t know a damn thing, you go talk to people who do. Andy Coop and Marty Adler were so helpful. A fundamental part of writing the book was when Marty said, “if we didn’t understand cancer, we would just prescribe the same treatment for all types of cancers. We are going to come one day, I think, to understand that pain is not all the same and is varied and we need a different treatment for each kind of pain”. I had not thought of that before. Andy and I talked about how in this one little morphine molecule you could have merciful freedom from excruciating pain. Soldiers blessed this drug out on the battlefield. You had heaven and hell in this one diminutive molecule. What could drive a person to sleep under an overpass and walk 5 miles every day to get his dope? I had been thinking about these kinds of things when I came to your meeting. The video that Dr. Volkow presented that shows heroin prices going from $3,500 a gram down to $500 a gram is crucial. In the 1980’s, the Columbians were developing their great cartel system that was very efficient and very powerful and the Mexicans were slowly doing the same thing, and the effect was to lower the price of heroin. They out-competition the Far Eastern heroin during those years, but no one paid attention at the time because we had issues with crack, meth, and other drugs. Over-prescription of Oxycontin took people’s tolerance of pain to very high levels. People then began to notice how cheap heroin had become and how the cartel had become as efficient at delivering drugs as Federal Express with the use of immigrant networks here in the US. When I started writing my book about drug trafficking and dope dealers, I started to understand that I was really writing a book about America -- who we are and who we have become as a culture, so averse to pain. The common denominator is why there is heroin in Portsmouth, OH and in the wealthiest suburbs of Charlotte, NC. What unites the common denominator is our own isolation. Keep in mind that this is a cultural story of isolation and what we’ve done to ourselves. I am very, very honored to be given this award. If you look in that pamphlet, I am “what’s wrong with this picture?” by quite a bit. I thank you so much.
Editor’s choice articles


Smoking-related outcomes and associations with tobacco-free policy in addiction treatment, 2015-2016

Joseph R Guydish, Deborah Yip, Thao Le, Noah Gubner, Kevin Delucchi, Paul Roman (Drug Alcohol Depend., in press)

This study assessed whether tobacco-free grounds policies were associated with smoking-related outcomes among clients enrolled in 25 addiction treatment programs surveyed in 2015 and 2016. In programs with tobacco-free grounds policies, compared to those without, cigarettes per day (CPD) and the rate of staff and clients smoking together were significantly lower. In two programs where tobacco-free grounds were implemented during study years, client smoking prevalence, the rate of staff and clients smoking together, and mean CPD decreased, while tobacco services received by clients increased. Addiction treatment programs should implement tobacco-free grounds policies to reduce tobacco use among clients.

Understanding the prevalence of lifetime abstinence from alcohol: an ecological study

Charlotte Probst, Jakob Manthey, Jürgen Rehm (Drug Alcohol Depend. 2017; 178: 126-129.)

The proportion of the population in a country that abstains from alcohol throughout their lifetime is an important indicator for the health burden and social harm caused by alcohol use in the respective country. We found that the proportion of lifetime abstainers from alcohol decreased strongly with increasing wealth of the country. This association, however, did not hold true in countries with a Muslim majority population. In those countries, the relative size of the Muslim population was a much stronger predictor, with a much higher proportions of lifetime abstainers from alcohol in countries with a higher proportion of Muslims.

80th Annual Meeting

LOCATION
Hilton Bayfront Hotel, San Diego, California

DATES
June 9th - 14th, 2018

DEADLINES

Symposiums
October 16th, 2017

Workshops
October 16th, 2017

Forums
October 16th, 2017

Abstract Submission
December 1st, 2017